Argenx SE (ARGX)

NASDAQ: ARGX · IEX Real-Time Price · USD
376.91
+2.77 (0.74%)
Aug 12, 2022 4:00 PM EDT - Market closed
0.74%
Market Cap 20.75B
Revenue (ttm) 31.04M
Net Income (ttm) -955.12M
Shares Out 55.06M
EPS (ttm) -11.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 330,485
Open 373.71
Previous Close 374.14
Day's Range 370.45 - 379.80
52-Week Range 249.50 - 387.89
Beta 0.80
Analysts Buy
Price Target 391.18 (+3.8%)
Earnings Date Jul 28, 2022

About ARGX

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical... [Read more...]

Industry Biotechnology
IPO Date May 18, 2017
CEO Tim Van Hauwermeiren
Employees 650
Stock Exchange NASDAQ
Ticker Symbol ARGX
Full Company Profile

Financial Performance

In 2021, Argenx SE's revenue was 497.28 million, an increase of 1,105.72% compared to the previous year's 41.24 million. Losses were -408.27 million, -32.90% less than in 2020.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for ARGX stock is "Buy." The 12-month stock price forecast is 391.18, which is an increase of 3.79% from the latest price.

Price Target
$391.18
(3.79% upside)
Analyst Consensus: Buy
Stock Forecasts

News

argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized M...

VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized myasthenia gravis ( gMG) who are anti-acetylcholine receptor (AChR) antibo...

Best Momentum Stocks to Buy for August 3rd

SSB, XOM and ARGX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 3, 2022.

Other symbols: SSBXOM

argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022

July 21, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced...

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myastheni...

Breda, the Netherlands— June 24 , 2022—argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced...

argenx to Present at Upcoming Investor Conferences

June 1 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced...

argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis

Positive scientific opinion under Early Access to Medicines Scheme (EAMS) will make efgartigimod available to eligible generali z ed myasthenia gravis (gMG) patients in the UK prior to marketing authori...

Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study

Argenx SE's (NASDAQ: ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint.  The ADVANCE trial enrolled 131 adult ...

argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary...

Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316) ; responders observed across patient types regardless o...

argenx to Present at BofA Securities 2022 Healthcare Conference

May 4 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022

April 28, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announce...

argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) i...

Interim data suggest long-term treatment with VYVGART provides improvement in generalized myasthenia gravis (gMG) disease scores that remains consistent over multiple treatment cycles

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Me...

BREDA, the Netherlands--(BUSINESS WIRE)--argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

argenx announces full exercise of underwriters' option to purchase additional ADSs

Regulated information — Inside information

argenx announces Annual General Meeting of Shareholders on May 10, 2022

March 2 9 , 20 2 2

argenx announces closing of global offering

Regulated information

argenx raises $700 million in gross proceeds in a global offering

Regulated information — Inside information

argenx (ARGX) Up on Positive Autoimmune Disorder Study Data

argenx (ARGX) plans to file a BLA for the SC formulation of efgartigimod, developed using Halozyme's ENHANZE technology, for treating myasthenia gravis disease, an autoimmune disorder, in 2022.

argenx announces launch of proposed global offering

Regulated information — Inside information

Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx

Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical company" to run a clinical trial for LUNAR-COV19 v...

Other symbols: ARCT

Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

Argenx SE (NASDAQ: ARGX) ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG).  Myasthenia gravis is a chronic a...